

Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



September 15, 2017

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street, Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 Code: LAURUSLABS
--	--

Dear Sirs,

Sub: Laurus Labs receives the EIR from USFDA, and also successfully completes the German Regulatory Authority for Unit 2 and WHO inspections for Units 1 & 3.


Laurus Labs Limited, a leading research and development driven pharmaceutical company has received the **Establishment Inspection Report (EIR)** from US Food and Drug Administration (US FDA) for its **Finished Dosage Formulations (FDF) & Active Pharmaceutical Ingredients (API's) manufacturing plant, Unit 2**, located at Atchutapuram, Vishakhapatnam, for the inspection completed in May 2017.

Unit 2 (FDF) has also completed the **BGV Hamburg (German Regulatory Authority)** inspection and **Units 1 & 3** located at Parawada, Visakhapatnam have completed **WHO (Geneva)** inspection successfully during this month with no critical or major observations.

The same is being sent herewith for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary

